Formulation and Drug Delivery

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

NCI launches trial to assess the utility of genetic sequencing to improve patient outcomes.

Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.

Products enable testing in accordance with methods described in new USP monograph.

Competition seeks to encourage academic research and accelerate drug delivery applications.

Cour Pharmaceutical Development Company, a biopharmaceutical company, has published new data showing that its proprietary nanoparticle therapy could potentially reduce inflammation and promote tissue repair and regeneration in patients who have had a heart attack.

A study led by Stanford University explains why men may have weaker responses to vaccines than women.

A monkey-vaccine study provides insight into HIV research.

NMR analysis provides crucial structural information of synthesized glycans while LC-MS/MS is ideal for quantitation of free sugars in biological matrices.

How will the move to more specialized and personalized medicines impact drug delivery and dosage forms?

Antibody fragments pose unique challenges in terms of recovery, purification, and formulation.

Emerging markets are an engine for growth in the custom-manufacturing and pharma markets.

Roger Hayes of MPI Research discusses highly potent drug development.

With SMEs gaining wider recognition as the powerhouse of research and innovation in Europe, regulatory agencies are urging companies to engage with regulators early in the drug-development process.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

A collaborative pharmaceutical project to develop paediatric formulations using smart design and predictive science has received the go ahead after securing a ?660,000 grant from UK-based Technology Strategy Board.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

FDA and EMA launch initiative to share bioequivalence inspection information.

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.

FDA details efforts to evaluate potential risks from use of nanomaterials in drug products and discuss analytical considerations, impact on stability, safety, and toxicology effects.

OGD is under pressure to improve review operations.

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).